Skip to main navigation Skip to search Skip to main content

Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel

  • Masatoshi Kubo
  • , Masaru Jida
  • , Masaomi Yamane
  • , Katsuya Miyatani
  • , Tetsunobu Udaka
  • , Osanori Sogabe
  • , Hiroya Maeda
  • , Minoru Mizuta
  • , Kazutoyo Shirakawa

Research output: Contribution to journalArticlepeer-review

Abstract

Carcinomatous meningitis from breast cancer is rare and has a poor prognosis with a life expectancy of approximately 80 days. We performed intrathecal MTX and Ara-C in combination with systemic docetaxel treatments in the patient, a 44-year-old woman with carcinomatous meningitis from invasive lobular carcinoma previously treated with anthracycline and paclitaxel. Although the patient died 128 days after the onset, intrathecal chemotherapy in combination with systemic docetaxel reduced the number of malignant cells and induced degeneration of the cells in CSF, resulting in improved quality of life.

Original languageEnglish
Pages (from-to)2097-2099
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume32
Issue number13
Publication statusPublished - Dec 2005
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel'. Together they form a unique fingerprint.

Cite this